Single-Dose, Open-Label Study of the Differences in Pharmacokinetics of Colchicine in Subjects with Renal Impairment, Including End-Stage Renal Disease

Clinical Drug Investigation

Volumn 34, Issue 12, 2014, Pages 845-855

  Wason, Suman ^a,d   Mount, David ^b,c   Faulkner, Robert ^a  

^a Mutual Pharmaceutical Company Inc ^*  (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c VA BOSTON HEALTHCARE SYSTEM   (United States)

^d LEXICON PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLCHICINE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIALYSATE; DIARRHEA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG SAFETY; DRUG URINE LEVEL; END STAGE RENAL DISEASE; FEMALE; HEADACHE; HEMODIALYSIS; HUMAN; KIDNEY CLEARANCE; KIDNEY DISEASE; KIDNEY FUNCTION; LOWER ABDOMINAL PAIN; MALE; MAXIMUM PLASMA CONCENTRATION; MIDDLE AGED; MILD RENAL IMPAIRMENT; MODERATE RENAL IMPAIRMENT; OPEN STUDY; PLASMA CONCENTRATION-TIME CURVE; SEVERE RENAL IMPAIRMENT; SINGLE DRUG DOSE; STEADY STATE; TIME TO MAXIMUM PLASMA CONCENTRATION; VOLUME OF DISTRIBUTION; YOUNG ADULT; COMPARATIVE STUDY; DRUG EFFECTS; KIDNEY; KIDNEY FAILURE, CHRONIC; METABOLISM; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ADULT; AGED; COLCHICINE; FEMALE; HUMANS; KIDNEY; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 84911967563     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.1007/s40261-014-0238-6     Document Type: Article

References (24)

1. Kim KY, Ralph Schumacher H, Hunsche E, Wertheimer AI, Kong SX. A literature review of the epidemiology and treatment of acute gout. Clin Ther. 2003;25:1593–617.
2. Molad Y. Update on colchicine and its mechanism of action. Curr Rheumatol Rep. 2002;4:252–6.
3. Schlesinger N. Management of acute and chronic gouty arthritis: present state-of-the-art. Drugs. 2004;64:2399–416.
4. Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007–2008. Arthritis Rheum. 2011;63:3136–41.
5. Zhu Y, Pandya BJ, Choi HK. Comorbidities of gout and hyperuricemia in the US general population: NHANES 2007–2008. Am J Med. 2012;125(679–87):e671.
6. Krishnan E. Reduced glomerular function and prevalence of gout: NHANES 2009–10. PLoS One. 2012;7:e50046.
7. Cohen SD, Kimmel PL, Neff R, Agodoa L, Abbott KC. Association of incident gout and mortality in dialysis patients. J Am Soc Nephrol. 2008;19:2204–10.
8. Food and Drug Administration. FDA approves colchicine for acute gout, mediterranean fever. Agency also provides new information to physicians regarding safe use of drug. 2009. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm174620.htm. Accessed 15 Oct 2013.
9. Colcrys (colchicine, USP) tablets for oral use. Full prescribing information. Deerfield, IL: Takeda Pharmaceuticals America, Inc.; 2012.
10. Wallace SL, Singer JZ, Duncan GJ, Wigley FM, Kuncl RW. Renal function predicts colchicine toxicity: guidelines for the prophylactic use of colchicine in gout. J Rheumatol. 1991;18:264–9.
11. Terkeltaub RA. Clinical practice. Gout. N Engl J Med. 2003;349:1647–55.
12. El-Zawawy H, Mandell BF. Managing gout: how is it different in patients with chronic kidney disease? Cleve Clin J Med. 2010;77:919–28.
13. Terkeltaub RA, Furst DE, Bennett K, Kook KA, Crockett RS, Davis MW. High versus low dosing of oral colchicine for early acute gout flare: twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis Rheum. 2010;62:1060–8.
14. Wason S, Faulkner RD, Davis MW. Are dosing adjustments required for colchicine in the elderly compared with younger patients? Adv Ther. 2012;29:551–61.
15. Sabouraud A, Chappey O, Dupin T, Scherrmann JM. Binding of colchicine and thiocolchicoside to human serum proteins and blood cells. Int J Clin Pharmacol Ther. 1994;32:429–32.
16. Tateishi T, Soucek P, Caraco Y, Guengerich FP, Wood AJ. Colchicine biotransformation by human liver microsomes. Identification of CYP3A4 as the major isoform responsible for colchicine demethylation. Biochem Pharmacol. 1997;53:111–6.
17. Leighton JA, Bay MK, Maldonado AL, Johnson RF, Schenker S, Speeg KV. The effect of liver dysfunction on colchicine pharmacokinetics in the rat. Hepatology. 1990;11:210–5.
18. Chen YJ, Huang SM, Liu CY, Yeh PH, Tsai TH. Hepatobiliary excretion and enterohepatic circulation of colchicine in rats. Int J Pharm. 2008;350:230–9.
19. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31–41.
20. Levey AS, Coresh J, Greene T, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med. 2006;145:247–54.
21. Berkun Y, Wason S, Brik R, et al. Pharmacokinetics of colchicine in pediatric and adult patients with familial Mediterranean fever. Int J Immunopathol Pharm. 2012;25:1121–30.
22. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), and Center for Biologics Evaluation and Research (CBER). Exposure-response relationships: study design, data analysis, and regulatory applications. 2003. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm072109.pdf. Accessed 15 Oct 2014.
23. Hanlon JT, Aspinall SL, Semla TP, et al. Consensus guidelines for oral dosing of primarily renally cleared medications in older adults. J Am Geriatr Soc. 2009;57:335–40.
24. Terkeltaub RA, Furst DE, Digiacinto JL, Kook KA, Davis MW. Novel evidence-based colchicine dose-reduction algorithm to predict and prevent colchicine toxicity in the presence of cytochrome P450 3A4/P-glycoprotein inhibitors. Arthritis Rheum. 2011;63:2226–37.